{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:03:39Z","timestamp":1790697819269,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes and Environ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic pulmonary fibrosis (IPF) represents another progressive and devastating interstitial lung disease found across populations, with a prominent male predominance accounting for approximately 70% of cases. Regional variation in IPF-related genetic polymorphisms, especially in the Americas, Europe, and Asia, points to a hereditary basis. Family history is the main risk factor. Rare mutations may alter outcomes through gene interactions. Environmental factors such as smoking can worsen genetic risk by epigenetic mechanisms like DNA methylation. Unlike studies that focus narrowly on specific genetic variants or processes, this study integrates the genetic variation map, multi-omics regulatory networks, and the effects of environmental exposures in IPF. This links clinical decision-making and gene discovery. This study examines mechanisms, therapies, and prognoses to clarify the impact of epigenetics and genetics on disease development. It also proposes using a multi-gene risk score (MGRS) to predict outcomes and design targeted treatments. The research advances the translation of basic knowledge into therapies. Theoretical and clinical support can aid doctors treating IPF.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical trial number<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Not applicable.<\/jats:p>","DOI":"10.1186\/s41021-026-00364-0","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:37:16Z","timestamp":1786977436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics insights into the mechanisms and prognosis of IPF"],"prefix":"10.1186","volume":"48","author":[{"given":"Dong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoutong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6771-3301","authenticated-orcid":false,"given":"Juan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0497-4221","authenticated-orcid":false,"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"10082","key":"364_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941\u201352.","journal-title":"Lancet"},{"key":"364_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.omtm.2021.01.003","volume":"20","author":"MJR Ruigrok","year":"2021","unstructured":"Ruigrok MJR, Frijlink HW, Melgert BN, Olinga P, Hinrichs WLJ. Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Mol Ther Methods Clin Dev. 2021;20:483\u201396.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"364_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40266-016-0366-1","volume":"33","author":"HE Jo","year":"2016","unstructured":"Jo HE, Randhawa S, Corte TJ, Moodley Y. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. Drugs Aging. 2016;33(5):321\u201334.","journal-title":"Drugs Aging"},{"issue":"1","key":"364_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12890-025-03836-1","volume":"25","author":"N Golchin","year":"2025","unstructured":"Golchin N, Patel A, Scheuring J, Wan V, Hofer K, Collet JP, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis. BMC Pulm Med. 2025;25(1):378.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"364_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.chest.2020.02.009","volume":"158","author":"T Zaman","year":"2020","unstructured":"Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS. Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study. Chest. 2020;158(1):245\u201351.","journal-title":"Chest"},{"issue":"7","key":"364_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","volume":"18","author":"TM Dempsey","year":"2021","unstructured":"Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2021;18(7):1121\u20138.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"364_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4046\/trd.2021.0123","volume":"85","author":"Y Jegal","year":"2022","unstructured":"Jegal Y, Park JS, Kim SY, Yoo H, Jeong SH, Song JW, et al. Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry. Tuberc Respir Dis (Seoul). 2022;85(2):185\u201394.","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"7","key":"364_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1164\/rccm.201905-0958LE","volume":"200","author":"EP Dove","year":"2019","unstructured":"Dove EP, Olson AL, Glassberg MK. Trends in Idiopathic Pulmonary Fibrosis-related Mortality in the United States: 2000\u20132017. Am J Respir Crit Care Med. 2019;200(7):929\u201331.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"364_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12931-024-02883-2","volume":"25","author":"CT Lee","year":"2024","unstructured":"Lee CT, Hao W, Burg CA, Best J, Kolenic GE, Strek ME. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024;25(1):255.","journal-title":"Respir Res"},{"issue":"10","key":"364_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/resp.14116","volume":"26","author":"MT Durheim","year":"2021","unstructured":"Durheim MT, Bendstrup E, Carlson L, Sutinen EM, Hyldgaard C, Kalafatis D, et al. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology. 2021;26(10):982\u20138.","journal-title":"Respirology"},{"key":"364_CR11","doi-asserted-by":"publisher","first-page":"329481","DOI":"10.1155\/2015\/329481","volume":"2015","author":"M Kreuter","year":"2015","unstructured":"Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int. 2015;2015:329481.","journal-title":"Biomed Res Int"},{"key":"364_CR12","doi-asserted-by":"publisher","first-page":"107798","DOI":"10.1016\/j.pharmthera.2020.107798","volume":"222","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, et al. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacol Ther. 2021;222:107798.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"364_CR13","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"364_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s40168-024-01893-y","volume":"12","author":"C Martin","year":"2024","unstructured":"Martin C, Mahan KS, Wiggen TD, Gilbertsen AJ, Hertz MI, Hunter RC, et al. Microbiome and metabolome patterns after lung transplantation reflect underlying disease and chronic lung allograft dysfunction. Microbiome. 2024;12(1):196.","journal-title":"Microbiome"},{"issue":"4","key":"364_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/aje\/152.4.307","volume":"152","author":"KB Baumgartner","year":"2000","unstructured":"Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers Am J Epidemiol. 2000;152(4):307\u201315.","journal-title":"Collaborating Centers Am J Epidemiol"},{"issue":"4","key":"364_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1513\/pats.200512-131TK","volume":"3","author":"VS Taskar","year":"2006","unstructured":"Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006;3(4):293\u20138.","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"364_CR17","first-page":"193","volume":"21","author":"M Gulati","year":"2015","unstructured":"Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. Curr Opin Pulm Med. 2015;21(2):193\u2013200.","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"364_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1164\/rccm.201905-1017OC","volume":"201","author":"RJ Allen","year":"2020","unstructured":"Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, et al. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020;201(5):564\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"364_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/thoraxjnl-2021-218577","volume":"77","author":"RJ Allen","year":"2022","unstructured":"Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, et al. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022;77(8):829\u201333.","journal-title":"Thorax"},{"issue":"2","key":"364_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/thorax-2023-220483","volume":"79","author":"I Hall","year":"2024","unstructured":"Hall I. Tobacco use: a smoking gun for IPF? Thorax. 2024;79(2):104\u20135.","journal-title":"Thorax"},{"issue":"129","key":"364_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1183\/09059180.00000713","volume":"22","author":"PL Molyneaux","year":"2013","unstructured":"Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22(129):376\u201381.","journal-title":"Eur Respir Rev"},{"key":"364_CR22","doi-asserted-by":"crossref","unstructured":"Bridges JP, Vladar EK, Kurche JS, Krivoi A, Stancil IT, Dobrinskikh E et al. Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium. J Clin Invest. 2025;135(1).","DOI":"10.1172\/JCI183836"},{"issue":"6","key":"364_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S2213-2600(25)00045-1","volume":"13","author":"A Alonso-Gonzalez","year":"2025","unstructured":"Alonso-Gonzalez A, Jaspez D, Lorenzo-Salazar JM, Ma SF, Strickland E, Mychaleckyj J, et al. Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation. Lancet Respir Med. 2025;13(6):495\u2013504.","journal-title":"Lancet Respir Med"},{"key":"364_CR24","doi-asserted-by":"crossref","unstructured":"He D, Guler SA, Shannon CP, Ryerson CJ, Tebbutt SJ. Transcriptomics of interstitial lung disease: a systematic review and meta-analysis. Eur Respir J. 2025;65(6).","DOI":"10.1183\/13993003.01070-2024"},{"issue":"10","key":"364_CR25","doi-asserted-by":"publisher","first-page":"7851","DOI":"10.1007\/s11033-020-05861-1","volume":"47","author":"H Yildirim","year":"2020","unstructured":"Yildirim H, Yildiz P, Coskunpinar E. Investigation of telomere related gene mutations in idiopathic pulmonary fibrosis. Mol Biol Rep. 2020;47(10):7851\u201360.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"364_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1152\/physrev.00046.2021","volume":"102","author":"JK Alder","year":"2022","unstructured":"Alder JK, Armanios M. Telomere-mediated lung disease. Physiol Rev. 2022;102(4):1703\u201320.","journal-title":"Physiol Rev"},{"key":"364_CR27","doi-asserted-by":"crossref","unstructured":"Roake CM, Artandi SE. Control of cellular aging, tissue function, and cancer by p53 downstream of telomeres. Cold Spring Harb Perspect Med. 2017;7(5).","DOI":"10.1101\/cshperspect.a026088"},{"issue":"3","key":"364_CR28","doi-asserted-by":"publisher","first-page":"e0248889","DOI":"10.1371\/journal.pone.0248889","volume":"16","author":"J Karman","year":"2021","unstructured":"Karman J, Wang J, Bodea C, Cao S, Levesque MC. Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms. PLoS ONE. 2021;16(3):e0248889.","journal-title":"PLoS ONE"},{"issue":"10","key":"364_CR29","doi-asserted-by":"publisher","first-page":"e70174","DOI":"10.1111\/acel.70174","volume":"24","author":"M Shi","year":"2025","unstructured":"Shi M, Wang W, Wan P, Shi J, Cui H, Sun Z, et al. Smoking Promotes AT2 Cell Senescence and Exacerbates Pulmonary Fibrosis by Downregulating POT1 via Integratively Inducing CpG Methylation and MECP2-Mediated FOXP2 Transcriptional Binding Inhibition. Aging Cell. 2025;24(10):e70174.","journal-title":"Aging Cell"},{"issue":"6","key":"364_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.202004-1274OC","volume":"203","author":"C Yao","year":"2021","unstructured":"Yao C, Guan X, Carraro G, Parimon T, Liu X, Huang G, et al. Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021;203(6):707\u201317.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"364_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.21037\/jtd-22-886","volume":"15","author":"M Tu","year":"2023","unstructured":"Tu M, Wei T, Jia Y, Wang Y, Wu J. Molecular mechanisms of alveolar epithelial cell senescence and idiopathic pulmonary fibrosis: a narrative review. J Thorac Dis. 2023;15(1):186\u2013203.","journal-title":"J Thorac Dis"},{"issue":"1","key":"364_CR32","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1038\/s41467-024-51336-3","volume":"15","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Nguyen MT, Choi HE, Stahl M, Kuhn AL, Van der Auwera S, et al. RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening. Nat Commun. 2024;15(1):7138.","journal-title":"Nat Commun"},{"issue":"11","key":"364_CR33","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1164\/rccm.202205-0845OC","volume":"207","author":"JM Oldham","year":"2023","unstructured":"Oldham JM, Allen RJ, Lorenzo-Salazar JM, Molyneaux PL, Ma S-F, Joseph C, et al. PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2023;207(11):1515\u201324.","journal-title":"Am J Respir Crit Care Med"},{"key":"364_CR34","doi-asserted-by":"crossref","unstructured":"Tian Q, Dijkhuis A, Remmerswaal EBM, Aberson H, Crestani B, van der Poll T et al. Epithelial PCSK6 Promotes proliferation and decreases collagen deposition by fibroblasts potentially via MMP activation. Int J Mol Sci. 2026;27(11).","DOI":"10.3390\/ijms27115104"},{"issue":"2","key":"364_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41385-020-00343-w","volume":"14","author":"J Milara","year":"2021","unstructured":"Milara J, Ballester B, Safont MJ, Artigues E, Escriva J, Morcillo E, et al. MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor beta inducing fibrotic responses. Mucosal Immunol. 2021;14(2):377\u201388.","journal-title":"Mucosal Immunol"},{"key":"364_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss BJ, Ryter SW, Rosas IO. Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis. Annu Rev Pathol. 2022;17:515\u201346.","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"364_CR37","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.21037\/jtd.2019.09.03","volume":"11","author":"T Nouno","year":"2019","unstructured":"Nouno T, Okamoto M, Ohnishi K, Kaieda S, Tominaga M, Zaizen Y, et al. Elevation of pulmonary CD163(+) and CD204(+) macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients. J Thorac Dis. 2019;11(9):4005\u201317.","journal-title":"J Thorac Dis"},{"key":"364_CR38","doi-asserted-by":"publisher","first-page":"1444964","DOI":"10.3389\/fimmu.2024.1444964","volume":"15","author":"Z Ge","year":"2024","unstructured":"Ge Z, Chen Y, Ma L, Hu F, Xie L. Macrophage polarization and its impact on idiopathic pulmonary fibrosis. Front Immunol. 2024;15:1444964.","journal-title":"Front Immunol"},{"key":"364_CR39","doi-asserted-by":"crossref","unstructured":"Morse C, Tabib T, Sembrat J, Buschur KL, Bittar HT, Valenzi E et al. Proliferating SPP1\/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J. 2019;54(2).","DOI":"10.1183\/13993003.02441-2018"},{"key":"364_CR40","doi-asserted-by":"crossref","unstructured":"Yang X, Liu Z, Zhou J, Guo J, Han T, Liu Y et al. SPP1 promotes the polarization of M2 macrophages through the Jak2\/Stat3 signaling pathway and accelerates the progression of idiopathic pulmonary fibrosis. Int J Mol Med. 2024;54(4).","DOI":"10.3892\/ijmm.2024.5413"},{"key":"364_CR41","doi-asserted-by":"publisher","first-page":"1450688","DOI":"10.3389\/fimmu.2024.1450688","volume":"15","author":"T Chen","year":"2024","unstructured":"Chen T, Sun W, Xu ZJ. The immune mechanisms of acute exacerbations of idiopathic pulmonary fibrosis. Front Immunol. 2024;15:1450688.","journal-title":"Front Immunol"},{"key":"364_CR42","doi-asserted-by":"crossref","unstructured":"Liu H, Cui H, Liu G. The Intersection between Immune system and idiopathic pulmonary fibrosis-a concise review. Fibros (Hong Kong). 2025;3(1).","DOI":"10.70322\/fibrosis.2025.10004"},{"issue":"9","key":"364_CR43","doi-asserted-by":"publisher","first-page":"e0183972","DOI":"10.1371\/journal.pone.0183972","volume":"12","author":"T Wang","year":"2017","unstructured":"Wang T, Liu Y, Zou JF, Cheng ZS. Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-beta1 mediated Smad2\/3 and ERK1\/2 activation. PLoS ONE. 2017;12(9):e0183972.","journal-title":"PLoS ONE"},{"issue":"38","key":"364_CR44","doi-asserted-by":"publisher","first-page":"14646","DOI":"10.1074\/jbc.RA117.001364","volume":"293","author":"Y Mitamura","year":"2018","unstructured":"Mitamura Y, Nunomura S, Nanri Y, Arima K, Yoshihara T, Komiya K, et al. Hierarchical control of interleukin 13 (IL-13) signals in lung fibroblasts by STAT6 and SOX11. J Biol Chem. 2018;293(38):14646\u201358.","journal-title":"J Biol Chem"},{"key":"364_CR45","doi-asserted-by":"crossref","unstructured":"Xu L, Li T, Cao Y, He Y, Shao Z, Liu S et al. PIEZO1 mediates periostin+ myofibroblast activation and pulmonary fibrosis in mice. J Clin Invest. 2025;135(11).","DOI":"10.1172\/JCI184158"},{"key":"364_CR46","doi-asserted-by":"publisher","first-page":"119857","DOI":"10.1016\/j.biomaterials.2020.119857","volume":"240","author":"J Yeo","year":"2020","unstructured":"Yeo J, Qiu Y, Jung GS, Zhang YW, Buehler MJ, Kaplan DL. Adverse effects of Alport syndrome-related Gly missense mutations on collagen type IV: Insights from molecular simulations and experiments. Biomaterials. 2020;240:119857.","journal-title":"Biomaterials"},{"issue":"3","key":"364_CR47","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.7150\/ijbs.65174","volume":"18","author":"ML Tan","year":"2022","unstructured":"Tan ML, Huang WJ, Wang Y, Liu L, Pan Y, Li JJ, et al. Integrin-beta4 regulates the dynamic changes of phenotypic characteristics in association with epithelial-mesenchymal transition (EMT) and RhoA activity in airway epithelial cells during injury and repair. Int J Biol Sci. 2022;18(3):1254\u201370.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"364_CR48","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1002\/jcp.30422","volume":"236","author":"W Jiang","year":"2021","unstructured":"Jiang W, Wang JM, Luo JH, Chen Y, Pi J, Ma XD, et al. Airway epithelial integrin beta4-deficiency exacerbates lipopolysaccharide-induced acute lung injury. J Cell Physiol. 2021;236(11):7711\u201324.","journal-title":"J Cell Physiol"},{"issue":"9","key":"364_CR49","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1073\/pnas.092134099","volume":"99","author":"F Zuo","year":"2002","unstructured":"Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A. 2002;99(9):6292\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"364_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00408-023-00652-4","volume":"201","author":"Y Fan","year":"2023","unstructured":"Fan Y, Zheng C, Ma R, Wang J, Yang S, Ye Q. MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis. Lung. 2023;201(6):571\u201380.","journal-title":"Lung"},{"issue":"5","key":"364_CR51","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00141013","volume":"43","author":"JW Chien","year":"2014","unstructured":"Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014;43(5):1430\u20138.","journal-title":"Eur Respir J"},{"issue":"2","key":"364_CR52","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1172\/JCI74942","volume":"125","author":"M Bueno","year":"2015","unstructured":"Bueno M, Lai YC, Romero Y, Brands J, St Croix CM, Kamga C, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest. 2015;125(2):521\u201338.","journal-title":"J Clin Invest"},{"issue":"5","key":"364_CR53","doi-asserted-by":"publisher","first-page":"L1084","DOI":"10.1152\/ajplung.00069.2019","volume":"318","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Cheresh P, Jablonski RP, Rachek L, Yeldandi A, Piseaux-Aillon R, et al. Mitochondrial 8-oxoguanine DNA glycosylase mitigates alveolar epithelial cell PINK1 deficiency, mitochondrial DNA damage, apoptosis, and lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2020;318(5):L1084\u201396.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"364_CR54","doi-asserted-by":"crossref","unstructured":"Wolters PJ. A recurring theme in pulmonary fibrosis genetics. Eur Respir J. 2017;49(5).","DOI":"10.1183\/13993003.00545-2017"},{"issue":"9","key":"364_CR55","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1164\/rccm.200112-123OC","volume":"165","author":"AQ Thomas","year":"2002","unstructured":"Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165(9):1322\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"364_CR56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ajhg.2008.11.010","volume":"84","author":"Y Wang","year":"2009","unstructured":"Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84(1):52\u20139.","journal-title":"Am J Hum Genet"},{"issue":"12","key":"364_CR57","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1084\/jem.20182351","volume":"216","author":"A Takezaki","year":"2019","unstructured":"Takezaki A, Tsukumo SI, Setoguchi Y, Ledford JG, Goto H, Hosomichi K, et al. A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis. J Exp Med. 2019;216(12):2724\u201335.","journal-title":"J Exp Med"},{"issue":"2","key":"364_CR58","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1164\/rccm.201902-0451OC","volume":"201","author":"Z Borok","year":"2020","unstructured":"Borok Z, Horie M, Flodby P, Wang H, Liu Y, Ganesh S, et al. Grp78 Loss in Epithelial Progenitors Reveals an Age-linked Role for Endoplasmic Reticulum Stress in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020;201(2):198\u2013211.","journal-title":"Am J Respir Crit Care Med"},{"key":"364_CR59","doi-asserted-by":"crossref","unstructured":"Zhou W, Zhuang Y, Sun J, Wang X, Zhao Q, Xu L et al. Variants of the ABCA3 gene might contribute to susceptibility to interstitial lung diseases in the Chinese population. Sci Rep. 2017;7(1).","DOI":"10.1038\/s41598-017-04486-y"},{"issue":"3","key":"364_CR60","doi-asserted-by":"publisher","first-page":"308","DOI":"10.18699\/VJGB-22-37","volume":"26","author":"RN Mustafin","year":"2022","unstructured":"Mustafin RN. Molecular genetics of idiopathic pulmonary fibrosis. Vavilov J Genet Breed. 2022;26(3):308\u201318.","journal-title":"Vavilov J Genet Breed"},{"issue":"1","key":"364_CR61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12931-024-02989-7","volume":"25","author":"B Yue","year":"2024","unstructured":"Yue B, Xiong D, Chen J, Yang X, Zhao J, Shao J, et al. SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K\/Akt\/mTOR pathway. Respir Res. 2024;25(1):362.","journal-title":"Respir Res"},{"issue":"1","key":"364_CR62","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-024-02011-y","volume":"9","author":"G Huang","year":"2024","unstructured":"Huang G, Yang X, Yu Q, Luo Q, Ju C, Zhang B, et al. Overexpression of STX11 alleviates pulmonary fibrosis by inhibiting fibroblast activation via the PI3K\/AKT\/mTOR pathway. Signal Transduct Target Ther. 2024;9(1):306.","journal-title":"Signal Transduct Target Ther"},{"key":"364_CR63","doi-asserted-by":"crossref","unstructured":"Chianese M, Screm G, Salton F, Confalonieri P, Trotta L, Barbieri M et al. Pirfenidone and nintedanib in pulmonary fibrosis: lights and shadows. pharmaceuticals (Basel). 2024;17(6).","DOI":"10.3390\/ph17060709"},{"issue":"Pt A","key":"364_CR64","doi-asserted-by":"publisher","first-page":"109409","DOI":"10.1016\/j.intimp.2022.109409","volume":"113","author":"W Yang","year":"2022","unstructured":"Yang W, Pan L, Cheng Y, Wu X, Tang B, Zhu H, et al. Nintedanib alleviates pulmonary fibrosis in vitro and in vivo by inhibiting the FAK\/ERK\/S100A4 signalling pathway. Int Immunopharmacol. 2022;113(Pt A):109409.","journal-title":"Int Immunopharmacol"},{"issue":"22","key":"364_CR65","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"key":"364_CR66","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.15420\/cfr.2021.30","volume":"8","author":"A Aimo","year":"2022","unstructured":"Aimo A, Spitaleri G, Nieri D, Tavanti LM, Meschi C, Panichella G, et al. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail Rev. 2022;8:e12.","journal-title":"Card Fail Rev"},{"issue":"18","key":"364_CR67","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"364_CR68","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40001-021-00601-y","volume":"26","author":"C Zang","year":"2021","unstructured":"Zang C, Zheng Y, Wang Y, Li L. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. Eur J Med Res. 2021;26(1):129.","journal-title":"Eur J Med Res"},{"issue":"7","key":"364_CR69","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/bph.70240","volume":"183","author":"Y Wang","year":"2025","unstructured":"Wang Y, Sun D, Dilixiati N, Wang D, Song Y, Ye Q, Nerandomilast. a PDE4B inhibitor, alleviates silica-induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF\u2010\u03b2\/Smad signalling. Br J Pharmacol. 2025;183(7):1445\u201364.","journal-title":"Br J Pharmacol"},{"key":"364_CR70","doi-asserted-by":"crossref","unstructured":"Nathan SD, Behr J, Cottin V, Lancaster L, Smith P, Deng CQ et al. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. BMJ Open Respiratory Res. 2022;9(1).","DOI":"10.1136\/bmjresp-2022-001310"},{"key":"364_CR71","doi-asserted-by":"crossref","unstructured":"Orfanos S, Deeney BT, Cao G, Karmacharya N, Ravi A, Koziol-White CJ et al. The differential effects of cAMP mobilizing agents on TGF-\u03b2-induced extracellular matrix in human lung-derived fibroblasts: insights into therapeutic targets for lung fibrosis. Respir Res. 2025;26(1).","DOI":"10.1186\/s12931-025-03387-3"},{"key":"364_CR72","doi-asserted-by":"crossref","unstructured":"Lee NC, Gutierrez-Rodrigues F, Shalhoub RN, Machado T, Lotter J, Alemu L et al. Danazol treatment for telomere biology disorders: long-term results of a phase I\/II study. Blood Adv. 2026;10(1):208\u201312.","DOI":"10.1182\/bloodadvances.2025017860"},{"key":"364_CR73","doi-asserted-by":"crossref","unstructured":"Mackintosh JA, Pietsch M, Lutzky V, Enever D, Bancroft S, Apte SH et al. TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respir Res. 2021;8(1).","DOI":"10.1136\/bmjresp-2021-001127"},{"key":"364_CR74","doi-asserted-by":"crossref","unstructured":"Hoffman TW, van Moorsel CHM, van der Vis JJ, Biesma DH, Grutters JC. No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis. ERJ Open Res. 2023;9(5).","DOI":"10.1183\/23120541.00131-2023"},{"issue":"9","key":"364_CR75","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1164\/rccm.202401-0116OC","volume":"209","author":"L Richeldi","year":"2024","unstructured":"Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, et al. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial. Am J Respir Crit Care Med. 2024;209(9):1132\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7683","key":"364_CR76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","volume":"552","author":"S Schafer","year":"2017","unstructured":"Schafer S, Viswanathan S, Widjaja AA, Lim WW, Moreno-Moral A, DeLaughter DM, et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature. 2017;552(7683):110\u20135.","journal-title":"Nature"},{"key":"364_CR77","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1126\/scitranslmed.aaw1237","volume":"11","author":"B Ng","year":"2019","unstructured":"Ng B, Dong J, D\u2019Agostino G, Viswanathan S, Widjaja AA, Lim WW, et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med. 2019;11:511.","journal-title":"Sci Transl Med"},{"issue":"1","key":"364_CR78","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s40001-025-02755-5","volume":"30","author":"J Zhou","year":"2025","unstructured":"Zhou J, An X, Xia X, Xiao W, Dou D, Li W, et al. Aging-associated interleukin-11 drives the molecular mechanism and targeted therapy of idiopathic pulmonary fibrosis. Eur J Med Res. 2025;30(1):542.","journal-title":"Eur J Med Res"},{"issue":"3","key":"364_CR79","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med. 2019;381(3):291\u20133.","journal-title":"N Engl J Med"},{"key":"364_CR80","doi-asserted-by":"crossref","unstructured":"Fiorentini E, Bonomi F, Peretti S, Orlandi M, Lepri G, Matucci Cerinic M et al. Potential role of JAK Inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data. Life (Basel). 2022;12(12).","DOI":"10.3390\/life12122101"},{"issue":"5","key":"364_CR81","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","volume":"154","author":"SM Palmer","year":"2018","unstructured":"Palmer SM, Snyder L, Todd JL, Soule B, Christian R, Anstrom K, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018;154(5):1061\u20139.","journal-title":"Chest"},{"issue":"2","key":"364_CR82","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","volume":"211","author":"TJ Corte","year":"2025","unstructured":"Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, et al. Efficacy and Safety of Admilparant, an LPA(1) Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025;211(2):230\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"364_CR83","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.chest.2025.04.003","volume":"168","author":"M Kreuter","year":"2025","unstructured":"Kreuter M, Maher TM, Wuyts WA, Valenzuela C, Hamblin M, Kim S, et al. Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis. Chest. 2025;168(3):677\u201387.","journal-title":"Chest"},{"issue":"5","key":"364_CR84","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","volume":"47","author":"G Raghu","year":"2016","unstructured":"Raghu G, Scholand MB, de Andrade J, Lancaster L, Mageto Y, Goldin J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47(5):1481\u201391.","journal-title":"Eur Respir J"},{"issue":"4","key":"364_CR85","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12079-019-00542-6","volume":"13","author":"A Leask","year":"2019","unstructured":"Leask A, Breathe. breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis. J Cell Communication Signal. 2019;13(4):441\u20132.","journal-title":"J Cell Communication Signal"},{"key":"364_CR86","unstructured":"Raghu G, Richeldi L, Fern\u00e1ndez P\u00e9rez ER, De Salvo MC, Silva RS, Song JW et al. Pamrevlumab for idiopathic pulmonary fibrosis. Jama. 2024;332(5)."},{"issue":"9","key":"364_CR87","doi-asserted-by":"publisher","first-page":"109636","DOI":"10.1016\/j.celrep.2021.109636","volume":"36","author":"KD Alysandratos","year":"2021","unstructured":"Alysandratos KD, Russo SJ, Petcherski A, Taddeo EP, Acin-Perez R, Villacorta-Martin C, et al. Patient-specific iPSCs carrying an SFTPC mutation reveal the intrinsic alveolar epithelial dysfunction at the inception of interstitial lung disease. Cell Rep. 2021;36(9):109636.","journal-title":"Cell Rep"},{"key":"364_CR88","doi-asserted-by":"crossref","unstructured":"Yang S, Liu P, Jiang Y, Wang Z, Dai H, Wang C. Therapeutic Applications of mesenchymal stem cells in idiopathic pulmonary fibrosis. Front Cell Dev Biol. 2021;9.","DOI":"10.3389\/fcell.2021.639657"},{"key":"364_CR89","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cells13242050","volume":"13","author":"N Ouji-Sageshima","year":"2024","unstructured":"Ouji-Sageshima N, Hiyama A, Kumamoto M, Kitabatake M, Hara A, Furukawa R, et al. Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients. Cells. 2024;13:24.","journal-title":"Cells"},{"issue":"1","key":"364_CR90","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13287-025-04490-4","volume":"16","author":"Y Chen","year":"2025","unstructured":"Chen Y, Li M, Yang J, Chen Y, Wang J. Engineerable mesenchymal stem cell-derived extracellular vesicles as promising therapeutic strategies for pulmonary fibrosis. Stem Cell Res Ther. 2025;16(1):367.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"364_CR91","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41419-023-05889-8","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Tong X, Liu S, Huang J, Zhang L, Zhang T, et al. AAV9-Tspyl2 gene therapy retards bleomycin-induced pulmonary fibrosis by modulating downstream TGF-beta signaling in mice. Cell Death Dis. 2023;14(6):389.","journal-title":"Cell Death Dis"},{"issue":"12","key":"364_CR92","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1164\/rccm.201304-0760OC","volume":"188","author":"DN O\u2019Dwyer","year":"2013","unstructured":"O\u2019Dwyer DN, Armstrong ME, Trujillo G, Cooke G, Keane MP, Fallon PG, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2013;188(12):1442\u201350.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"364_CR93","doi-asserted-by":"publisher","first-page":"e18573","DOI":"10.1016\/j.heliyon.2023.e18573","volume":"9","author":"A Kubbara","year":"2023","unstructured":"Kubbara A, Amundson WH, Herman A, Lee AM, Bishop JR, Kim HJ. Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone. Heliyon. 2023;9(8):e18573.","journal-title":"Heliyon"},{"key":"364_CR94","doi-asserted-by":"crossref","unstructured":"Higuchi T, Oka S, Furukawa H, Shimada K, Tsunoda S, Ito S et al. Association of a single nucleotide variant in tert with airway disease in japanese rheumatoid arthritis patients. Genes (Basel). 2023;14(11).","DOI":"10.3390\/genes14112084"},{"key":"364_CR95","doi-asserted-by":"crossref","unstructured":"Berger K, Konkol S, Ma S-F, Whalen W, Simmons W, Joseph C et al. PCSK6 and clinical outcomes in the pulmonary fibrosis foundation patient registry. Respir Res. 2026;27(1).","DOI":"10.1186\/s12931-026-03642-1"},{"key":"364_CR96","doi-asserted-by":"publisher","first-page":"106739","DOI":"10.1016\/j.biocel.2025.106739","volume":"180","author":"A Valand","year":"2025","unstructured":"Valand A, Rajasekar P, Wain LV, Clifford RL. Interplay between genetics and epigenetics in lung fibrosis. Int J Biochem Cell Biol. 2025;180:106739.","journal-title":"Int J Biochem Cell Biol"},{"key":"364_CR97","doi-asserted-by":"crossref","unstructured":"Gandhi S, Tonelli R, Murray M, Samarelli AV, Spagnolo P. Environmental causes of idiopathic pulmonary fibrosis. Int J Mol Sci. 2023;24(22).","DOI":"10.3390\/ijms242216481"},{"key":"364_CR98","doi-asserted-by":"crossref","unstructured":"Cui F, Sun Y, Xie J, Li D, Wu M, Song L et al. Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis. Eur Respir J. 2023;61(2).","DOI":"10.1183\/13993003.00777-2022"},{"issue":"5","key":"364_CR99","doi-asserted-by":"publisher","first-page":"e10680","DOI":"10.1371\/journal.pone.0010680","volume":"5","author":"A Diaz de Leon","year":"2010","unstructured":"Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS ONE. 2010;5(5):e10680.","journal-title":"PLoS ONE"},{"issue":"2","key":"364_CR100","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1172\/JCI78554","volume":"125","author":"SE Stanley","year":"2015","unstructured":"Stanley SE, Chen JJ, Podlevsky JD, Alder JK, Hansel NN, Mathias RA, et al. Telomerase mutations in smokers with severe emphysema. J Clin Invest. 2015;125(2):563\u201370.","journal-title":"J Clin Invest"},{"key":"364_CR101","doi-asserted-by":"crossref","unstructured":"Sauleda J, Nunez B, Sala E, Soriano JB. Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes. Med Sci (Basel). 2018;6(4).","DOI":"10.3390\/medsci6040110"},{"key":"364_CR102","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/CLEP.S54815","volume":"5","author":"B Ley","year":"2013","unstructured":"Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483\u201392.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"364_CR103","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1152\/physrev.00004.2016","volume":"96","author":"CM Evans","year":"2016","unstructured":"Evans CM, Fingerlin TE, Schwarz MI, Lynch D, Kurche J, Warg L, et al. Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiol Rev. 2016;96(4):1567\u201391.","journal-title":"Physiol Rev"},{"issue":"4","key":"364_CR104","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1164\/rccm.202401-0238SO","volume":"210","author":"A Adegunsoye","year":"2024","unstructured":"Adegunsoye A, Kropski JA, Behr J, Blackwell TS, Corte TJ, Cottin V, et al. Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024;210(4):401\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"364_CR105","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1164\/rccm.202208-1591ED","volume":"206","author":"CA Bonham","year":"2022","unstructured":"Bonham CA, Noth I. Idiopathic Pulmonary Fibrosis Genetic Risk Factors, Function, and Mechanisms? The Concepts Are Starting to Gel. Am J Respir Crit Care Med. 2022;206(10):1197\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"364_CR106","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.trsl.2014.03.011","volume":"165","author":"IV Yang","year":"2015","unstructured":"Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Transl Res. 2015;165(1):48\u201360.","journal-title":"Transl Res"},{"key":"364_CR107","doi-asserted-by":"publisher","first-page":"730186","DOI":"10.3389\/fimmu.2022.730186","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Gu L, Li W. The Prognostic Value of Integrated Analysis of Inflammation and Hypoxia-Related Genes in Idiopathic Pulmonary Fibrosis. Front Immunol. 2022;13:730186.","journal-title":"Front Immunol"},{"key":"364_CR108","doi-asserted-by":"publisher","first-page":"1049361","DOI":"10.3389\/fimmu.2022.1049361","volume":"13","author":"G Fan","year":"2022","unstructured":"Fan G, Liu J, Wu Z, Li C, Zhang Y. Development and validation of the prognostic model based on autophagy-associated genes in idiopathic pulmonary fibrosis. Front Immunol. 2022;13:1049361.","journal-title":"Front Immunol"},{"issue":"3","key":"364_CR109","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1039\/D3LC00886J","volume":"24","author":"Z Rahman","year":"2024","unstructured":"Rahman Z, Bordoloi AD, Rouhana H, Tavasso M, van der Zon G, Garbin V, et al. Interstitial flow potentiates TGF-beta\/Smad-signaling activity in lung cancer spheroids in a 3D-microfluidic chip. Lab Chip. 2024;24(3):422\u201333.","journal-title":"Lab Chip"},{"key":"364_CR110","doi-asserted-by":"publisher","first-page":"116130","DOI":"10.1016\/j.bcp.2024.116130","volume":"223","author":"DVN Somanader","year":"2024","unstructured":"Somanader DVN, Zhao P, Widdop RE, Samuel CS. The involvement of the Wnt\/beta-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin. Biochem Pharmacol. 2024;223:116130.","journal-title":"Biochem Pharmacol"},{"key":"364_CR111","doi-asserted-by":"publisher","first-page":"114653","DOI":"10.1016\/j.intimp.2025.114653","volume":"155","author":"F Gao","year":"2025","unstructured":"Gao F, Pan L, Liu W, Chen J, Wang Y, Li Y, et al. Idiopathic pulmonary fibrosis microenvironment: Novel mechanisms and research directions. Int Immunopharmacol. 2025;155:114653.","journal-title":"Int Immunopharmacol"},{"key":"364_CR112","doi-asserted-by":"publisher","first-page":"118267","DOI":"10.1016\/j.biopha.2025.118267","volume":"189","author":"TL Hsia","year":"2025","unstructured":"Hsia TL, Chiou WC, Huang HC, Liu HK, Chen JC, Fu PK, et al. Ugonin L ameliorates pulmonary fibrosis as a novel TbetaRs inhibitor by regulating the TGF-beta\/TbetaRs signaling and autophagy. Biomed Pharmacother. 2025;189:118267.","journal-title":"Biomed Pharmacother"},{"key":"364_CR113","doi-asserted-by":"crossref","unstructured":"Burgy O, Konigshoff M. Teatime: epigallocatechin gallate targets fibroblast-epithelial cell crosstalk to combat lung fibrosis. J Clin Invest. 2024;134(18).","DOI":"10.1172\/JCI183970"},{"key":"364_CR114","doi-asserted-by":"crossref","unstructured":"Cohen ML, Brumwell AN, Ho TC, Garakani K, Montas G, Leong D et al. A fibroblast-dependent TGF-beta1\/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis. J Clin Invest. 2024;134(18).","DOI":"10.1172\/JCI174598"},{"issue":"1","key":"364_CR115","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1186\/s12967-023-04668-5","volume":"21","author":"X Cheng","year":"2023","unstructured":"Cheng X, Feng Z, Pan B, Liu Q, Han Y, Zou L, et al. Establishment and application of the BRP prognosis model for idiopathic pulmonary fibrosis. J Transl Med. 2023;21(1):805.","journal-title":"J Transl Med"},{"issue":"3","key":"364_CR116","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s41030-025-00302-5","volume":"11","author":"IE Montero","year":"2025","unstructured":"Montero IE, Hernandez-Gonzalez F, Sellares J. Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review. Pulm Ther. 2025;11(3):347\u201363.","journal-title":"Pulm Ther"},{"key":"364_CR117","doi-asserted-by":"publisher","first-page":"1152211","DOI":"10.3389\/fmed.2023.1152211","volume":"10","author":"A Alonso-Gonzalez","year":"2023","unstructured":"Alonso-Gonzalez A, Tosco-Herrera E, Molina-Molina M, Flores C. Idiopathic pulmonary fibrosis and the role of genetics in the era of precision medicine. Front Med (Lausanne). 2023;10:1152211.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"364_CR118","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.7150\/ijms.113226","volume":"22","author":"J Liu","year":"2025","unstructured":"Liu J, Yi Z, Chen T, Ying Y, Hu Y. An Overview of the Role of Genetic factors in Idiopathic Pulmonary Fibrosis: Insights from Epidemiology to Prognosis. Int J Med Sci. 2025;22(12):2992\u20133006.","journal-title":"Int J Med Sci"},{"issue":"5","key":"364_CR119","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1164\/rccm.201911-2286ED","volume":"201","author":"P Spagnolo","year":"2020","unstructured":"Spagnolo P, Kropski JA. Genome-Wide Association Studies in Idiopathic Pulmonary Fibrosis: Bridging the Gap between Sequence and Consequence. Am J Respir Crit Care Med. 2020;201(5):508\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"364_CR120","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12967-025-06368-8","volume":"23","author":"Z Wen","year":"2025","unstructured":"Wen Z, Liang W, Yang Z, Liu J, Yang J, Xu R, et al. Genetic insights into idiopathic pulmonary fibrosis: a multi-omics approach to identify potential therapeutic targets. J Transl Med. 2025;23(1):337.","journal-title":"J Transl Med"},{"issue":"10","key":"364_CR121","doi-asserted-by":"publisher","first-page":"100181","DOI":"10.1016\/j.xgen.2022.100181","volume":"2","author":"JJ Partanen","year":"2022","unstructured":"Partanen JJ, Happola P, Zhou W, Lehisto AA, Ainola M, Sutinen E, et al. Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics. Cell Genom. 2022;2(10):100181.","journal-title":"Cell Genom"},{"issue":"8","key":"364_CR122","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/thorax-2021-217703","volume":"78","author":"M Chen","year":"2023","unstructured":"Chen M, Zhang Y, Adams T, Ji D, Jiang W, Wain LV, et al. Integrative analyses for the identification of idiopathic pulmonary fibrosis-associated genes and shared loci with other diseases. Thorax. 2023;78(8):792\u20138.","journal-title":"Thorax"},{"issue":"8","key":"364_CR123","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41588-024-01819-2","volume":"56","author":"L Franzen","year":"2024","unstructured":"Franzen L, Olsson Lindvall M, Huhn M, Ptasinski V, Setyo L, Keith BP, et al. Mapping spatially resolved transcriptomes in human and mouse pulmonary fibrosis. Nat Genet. 2024;56(8):1725\u201336.","journal-title":"Nat Genet"},{"issue":"1","key":"364_CR124","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00018-021-04094-0","volume":"79","author":"P Zheng","year":"2022","unstructured":"Zheng P, Sun S, Wang J, Cheng ZJ, Lei KC, Xue M, et al. Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis. Cell Mol Life Sci. 2022;79(1):66.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"364_CR125","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-023-02435-0","volume":"24","author":"P Ruan","year":"2023","unstructured":"Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, et al. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023;24(1):141.","journal-title":"Respir Res"},{"key":"364_CR126","doi-asserted-by":"publisher","first-page":"112766","DOI":"10.1016\/j.intimp.2024.112766","volume":"139","author":"Z Ran","year":"2024","unstructured":"Ran Z, Mu BR, Zhu T, Zhang Y, Luo JX, Yang X, et al. Predicting biomarkers related to idiopathic pulmonary fibrosis: Robust ranking aggregation analysis and animal experiment verification. Int Immunopharmacol. 2024;139:112766.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"364_CR127","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pccm.2024.04.003","volume":"2","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Peng F, Zhou Y. Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction. Chin Med J Pulm Crit Care Med. 2024;2(2):72\u20139.","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"1","key":"364_CR128","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12931-025-03326-2","volume":"26","author":"M Dong","year":"2025","unstructured":"Dong M, Hu G, Chen X, Zhang L, Zhang Y, Fang Y, et al. The exosomal protein biomarkers auxiliary in diagnosis of interstitial lung disease. Respir Res. 2025;26(1):255.","journal-title":"Respir Res"},{"issue":"1","key":"364_CR129","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12967-024-05034-9","volume":"22","author":"W Gan","year":"2024","unstructured":"Gan W, Song W, Gao Y, Zheng X, Wang F, Zhang Z, et al. Exosomal circRNAs in the plasma serve as novel biomarkers for IPF diagnosis and progression prediction. J Transl Med. 2024;22(1):264.","journal-title":"J Transl Med"},{"issue":"41","key":"364_CR130","doi-asserted-by":"publisher","first-page":"27997","DOI":"10.1021\/acsnano.4c06139","volume":"18","author":"J Zhao","year":"2024","unstructured":"Zhao J, Yu W, Zhou D, Liu Y, Wei J, Bi L, et al. Delineating, Imaging, and Assessing Pulmonary Fibrosis Remodeling via Collagen Hybridization. ACS Nano. 2024;18(41):27997\u20138011.","journal-title":"ACS Nano"},{"issue":"1","key":"364_CR131","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.amjmed.2025.07.027","volume":"139","author":"MD Feist","year":"2026","unstructured":"Feist MD, Huang Y, Kalluri M, Cole J, Naikyar E, Boulanger P, et al. Decoding objective cough features in progressive pulmonary fibrosis: A 6-month feasibility study. Am J Med. 2026;139(1):99\u2013107. e9.","journal-title":"Am J Med"},{"key":"364_CR132","doi-asserted-by":"crossref","unstructured":"Karthik A, Patthi S, Maheswari BU, Devi JS, Pradhan AK, Balaji G et al. Advancing idiopathic pulmonary fibrosis prognosis through integrated CNN-LSTM predictive modeling and uncertainty quantification. Biomed Signal Process Control. 2025;100.","DOI":"10.1016\/j.bspc.2024.106811"}],"container-title":["Genes and Environment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41021-026-00364-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41021-026-00364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41021-026-00364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:13:44Z","timestamp":1790694824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41021-026-00364-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s41021-026-00364-0","relation":{},"ISSN":["1880-7062"],"issn-type":[{"value":"1880-7062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"16"}}